Quarterly ResultMay 13, 2026, 04:19 PM
Longeveron Q1 Net Loss $4.7M; HLHS Trial Results Expected August 2026
AI Summary
Longeveron Inc. reported its first-quarter 2026 financial results, with a net loss of $4.7 million, an improvement from $5.0 million in Q1 2025. Revenues remained stable at $0.4 million. The company is on track to release top-line results from its Phase 2b clinical trial for Hypoplastic Left Heart Syndrome (HLHS) in August 2026. Longeveron also completed a private placement of $15 million, part of a larger $30 million deal, and is actively seeking strategic partnerships for its laromestrocel development programs.
Key Highlights
- Net loss decreased to $4.7 million in Q1 2026 from $5.0 million in Q1 2025.
- Basic and diluted net loss per share improved to $(0.19) from $(0.34) year-over-year.
- Revenues were $0.4 million in Q1 2026, consistent with Q1 2025.
- Cash and cash equivalents stood at $15.8 million as of March 31, 2026, with a runway into Q4 2026.
- Top-line results for Phase 2b HLHS clinical trial (ELPIS II) anticipated in August 2026.
- Completed a private placement of $15 million, with potential for an additional $15 million.
- Stephen H. Willard appointed Chief Executive Officer in February 2026.
- Seeking strategic collaborations for laromestrocel in Alzheimer's disease.